Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S WOODWARD

Showing results (321-330 of 331) with videos related to

Pageof 34
Sort By:
The Journal of Clinical Investigation|April 3, 2025
Safety and implementation of phase I randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newbornsAvy Violari, Kennedy Otwombe, William Hahn, et al.
Annals of Internal Medicine|April 28, 2025
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)Sharon A Riddler, Zoe Moodie, Jesse Clark, et al.
The New Phytologist|October 13, 2012
Biogeographical patterns and determinants of invasion by forest pathogens in EuropeA Santini, L Ghelardini, C De Pace, et al.
Psychological Medicine|October 7, 2020
Comparing psychotic experiences in low-and-middle-income-countries and high-income-countries with a focus on measurement invarianceEdo S Jaya, Caroline Wüsten, Behrooz Z Alizadeh, et al.
Journal of the International AIDS Society|June 4, 2025
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical dataShelly Karuna, Fatima Laher, Sufia Dadabhai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2024
COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled TrialsAmy C Sherman, Jessica Tuan, Valeria D Cantos, et al.
The Journal of Infectious Diseases|October 5, 2023
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, et al.
Biogeochemistry|February 4, 2020
An approach for the identification of exemplar sites for scaling up targeted field observations of benthic biogeochemistry in heterogeneous environmentsC E L Thompson, B Silburn, M E Williams, et al.
The Journal of Experimental Medicine|September 5, 2024
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodiesWilliam O Hahn, K Rachael Parks, Mingchao Shen, et al.
Medrxiv : the Preprint Server for Health Sciences|May 20, 2024
HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodiesWilliam O Hahn, K Rachael Parks, Mingchao Shen, et al.
Pageof 34

Showing results (321-330 of 331) with videos related to

Sort By:
Pageof 34
The Journal of Clinical Investigation|April 3, 2025
Safety and implementation of phase I randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newbornsAvy Violari, Kennedy Otwombe, William Hahn, et al.
Annals of Internal Medicine|April 28, 2025
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)Sharon A Riddler, Zoe Moodie, Jesse Clark, et al.
The New Phytologist|October 13, 2012
Biogeographical patterns and determinants of invasion by forest pathogens in EuropeA Santini, L Ghelardini, C De Pace, et al.
Psychological Medicine|October 7, 2020
Comparing psychotic experiences in low-and-middle-income-countries and high-income-countries with a focus on measurement invarianceEdo S Jaya, Caroline Wüsten, Behrooz Z Alizadeh, et al.
Journal of the International AIDS Society|June 4, 2025
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical dataShelly Karuna, Fatima Laher, Sufia Dadabhai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2024
COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled TrialsAmy C Sherman, Jessica Tuan, Valeria D Cantos, et al.
The Journal of Infectious Diseases|October 5, 2023
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, et al.
Biogeochemistry|February 4, 2020
An approach for the identification of exemplar sites for scaling up targeted field observations of benthic biogeochemistry in heterogeneous environmentsC E L Thompson, B Silburn, M E Williams, et al.
The Journal of Experimental Medicine|September 5, 2024
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodiesWilliam O Hahn, K Rachael Parks, Mingchao Shen, et al.
Medrxiv : the Preprint Server for Health Sciences|May 20, 2024
HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodiesWilliam O Hahn, K Rachael Parks, Mingchao Shen, et al.
Pageof 34